Results 111 to 120 of about 552 (131)

Olokizumab's Effectiveness and Safety in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of Clinical Densitometry, 2023
In the development of rheumatoid arthritis, the cytokine interleukin-6 plays a role. An interleukin-6 cytokine-specific monoclonal antibody called olokizumab directly targets this cytokine. OKZ effectiveness and safety are being evaluated through this meta-analysis.I looked up every published randomized controlled study on Clinicaltrials.gov, Scopus ...
Abdelrahman Mohamed Mahmoud
exaly   +3 more sources

Model‐Based Optimal Design and Execution of the First‐Inpatient Trial of the Anti‐IL‐6, Olokizumab [PDF]

CPT: Pharmacometrics and Systems Pharmacology, 2014
The first‐in‐patient study for olokizumab (OKZ) employed model‐based, optimal design and adaptive execution to define the concentration–C‐reactive protein (CRP) suppression response. Modeling and exploratory statistics activities involved: reverse engineering of first‐in‐class (tocilizumab) pharmacokinetic/pharmacodynamic (PK/PD) models, adaptation of ...
B Boulanger
exaly   +3 more sources

Inflammation‐mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis

British Journal of Clinical Pharmacology
AbstractAimsIn patients with rheumatoid arthritis (RA), interleukin (IL)‐6 affects the activity of cytochrome P450 (CYP) enzymes. Treatment with anti‐IL‐6 therapy can reverse the IL‐6‐mediated downregulation of CYP enzymes, resulting in changes in plasma levels of CYP substrates.
Svetlana Agachi, Marina I Beloukhova, Maria Lemak   +2 more
exaly   +3 more sources

Olokizumab/tofacitinib/unspecified antibacterials

Reactions Weekly, 2023
openaire   +1 more source

Comparison of the efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials

Zeitschrift Fur Rheumatologie, 2023
Young Ho Lee, Gwan Gyu Song, Lee Young Ho   +2 more
exaly  

Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials

Zeitschrift Fur Rheumatologie, 2023
Young Ho Lee, Gwan Gyu Song
exaly  

POS1071 THE IMPACT OF COMORBIDITIES ON THE EFFICACY OF IL-6 INHIBITOR OLOKIZUMAB COMPARED TO ADALIMUMAB

Annals of the Rheumatic Diseases, 2023
E. Feist, M.E. Luggen, E. Nasonov, S. Yakushin, D. Bukhanova, A. Egorova, S. Grishin, M. Samsonov, J.S. Smolen   +8 more
openaire   +1 more source

Tocilizumab, baricitinib, olokizumab and dexamethasone: comparative characteristics and prognosis of efficacy in COVID-19

Therapy, 2022
Kabanov M.Yu. Kabanov, Bakulin I.G. Bakulin, Sukhomlinova I.M. Sukhomlinova   +2 more
openaire   +1 more source

POS0639 SWITCHING FROM IL-6R ANTAGONISTS TO OLOKIZUMAB, A DIRECT IL-6 INHIBITOR

Annals of the Rheumatic Diseases, 2023
E. Feist, E. Nasonov
openaire   +1 more source

Direkter Interleukin-6-Inhibitor Olokizumab wirkt gegen rheumatoide Arthritis

Orthopädie & Rheuma, 2022
openaire   +1 more source